8-K Announcements
6Material company update
May 11, 2026·SEC
Material company update
Apr 13, 2026·SEC
Material company update
Mar 9, 2026·SEC
Septerna, Inc.(SEPN)Earnings, Financials & Key Ratios
SEPN•NASDAQ
$37.34
Price updated Jun 27, 2026
AboutSepterna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products candidates for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. The company develops SEP-786, an oral small molecule PTH1R agonist for hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 NAM for chronic spontaneous urticaria and other mast cell diseases; TSHR Program, an oral small molecule TSHR NAM for Graves' disease and thyroid eye disease. It also develops oral small molecule single- and multi-incretin receptor agonists for metabolic disorders including obesity and type 2 diabetes. Septerna, Inc. was formerly known as GPCR NewCo, Inc. and changed its name to Septerna Inc. in June 2021. The company was incorporated in 2019 and is headquartered in South San Francisco, California.Show more
- Revenue$46M+4174.5%
- EBITDA-$79M+0.3%
- Net Income-$49M+31.9%
- EPS (Diluted)-1.10+43.0%
- Gross Margin100%
- EBITDA Margin-172.34%+97.7%
- Operating Margin-175.83%+97.7%
- Net Margin-106.37%+98.4%
- ROE-12.19%+67.6%
SEPN Price & Volume
Septerna, Inc. (SEPN) stock price & volume — 10-year historical chart
Loading chart...
Milestone Dependency Masks Persistent Operational Cash Burn
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Mixed
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Clinical trial milestone dependency
Key Thesis Takeaways
- Septerna operates as a high-risk, clinical-stage biotechnology firm whose financial viability is tethered to the unpredictable timing of non-recurring milestone payments rather than sustainable commercial revenue.
- While the company maintains a 98.4% gross margin as of 2026Q1, the lack of operational leverage and a deepening retained earnings deficit of $175.9 million highlight significant long-term solvency concerns.
- Investors should remain cautious as the rapid depletion of cash reserves from $320.0 million in 2025Q3 to $71.6 million in 2026Q1 necessitates a potential near-term capital raise to sustain ongoing R&D intensity.
Verdict Logic
the company's reliance on milestone-driven revenue and the rapid depletion of cash reserves to $71.6 million in 2026Q1 present an unsustainable financial trajectory for long-term investors.
SEPN Growth Metrics
Septerna, Inc. (SEPN) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM7295.6%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM54.44%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM59.7%
Return on Capital
10 Years-33.55%
5 Years-33.55%
3 Years-14.25%
Last Year-16.96%
SEPN Recent Earnings
Septerna, Inc. (SEPN) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 2/9 qtrs (29%)●Beat Revenue 3/9 qtrs (60%)
Q2 2026Latest
May 12, 2026Metric
Actual
Est
EPS
$0.19+62.7%
$0.51
Rev
$27M+56.2%
$17M
Q2 2026
Mar 9, 2026Metric
Actual
Est
EPS
$0.24-4.3%
$0.23
Rev
$24M+32.5%
$18M
Q4 2025
Nov 10, 2025Metric
Actual
Est
EPS
$0.09-147.4%
$0.19
Rev
$21M+24.5%
$17M
Q3 2025
Aug 11, 2025Metric
Actual
Est
EPS
$0.56-1020.0%
$0.05
Rev
$119,000-97.6%
$5M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 12, 2026 | $0.19vs $0.51+62.7% | $27Mvs $17M+56.2% |
| Q2 2026 | Mar 9, 2026 | $0.24vs $0.23-4.3% | $24Mvs $18M+32.5% |
| Q4 2025 | Nov 10, 2025 | $0.09vs $0.19-147.4% | $21Mvs $17M+24.5% |
| Q3 2025 | Aug 11, 2025 | $0.56vs $0.05-1020.0% | $119,000vs $5M-97.6% |
Based on last 9 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Septerna, Inc. (SEPN)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $37.34 | $1.68B | -33.95 | 4174.51% | -106.37% | -12.19% | — | |
| $108.12 | $8.83B | -29.30 | -16.72% | -612.17% | -25.02% | — | |
| $3.52 | $1.57B | -2.44 | 26.92% | -844.46% | -54.32% | — | |
| $38.04 | $4.41B | -11.92 | — | — | -71.31% | — | |
| $49.71 | $2.86B | -20.71 | — | — | -15.14% | — | |
| $115.07 | $6.73B | -28.27 | -79.35% | -1027.25% | -55.42% | — |
Compare SEPN vs Peers
Septerna, Inc. (SEPN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
SEPN SEC Filings & Documents
Septerna, Inc. (SEPN) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when SEPN posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
SEPN Frequently Asked Questions
Septerna, Inc. (SEPN) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Septerna, Inc.'s revenue?
Septerna, Inc. (SEPN) reported $72.3M in revenue for fiscal year 2025.
How fast is Septerna, Inc. growing?
Septerna, Inc. (SEPN) grew revenue by 4174.5% over the past year. This is strong growth.
Is SEPN profitable?
Septerna, Inc. (SEPN) reported a net loss of $36.0M for fiscal year 2025.
Dividend & Returns
What is SEPN's return on equity?
Septerna, Inc. (SEPN) has a return on equity (ROE) of -12.2%. Negative ROE indicates the company is unprofitable.
What is Septerna, Inc.'s free cash flow?
Septerna, Inc. (SEPN) generated $106.9M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.